BPH

Embolization for BPH shows long-term safety, efficacyFindings of a retrospective study including 1,000 men with follow-up ranging to 8 years demonstrate the long-term safety and efficacy of prostatic artery embolization for relieving lower urinary tract symptoms secondary to BPH, researchers reported at the Society of Interventional Radiology annual scientific meeting in Washington.
Urologists show low adherence to value-based care pathwayUrologists’ adherence to value-based care pathways for BPH surgery is extremely low and only modestly improved when given individualized feedback on patient outcomes, costs, and practice patterns relative to peers, say UCLA researchers.
5-ARIs linked to increased risk of self-harm, depressionUse of 5α-reductase inhibitors for the treatment of BPH appears to be associated with increased risks of self-harm and depression, according to a population-based, retrospective, matched cohort study of men in Canada.
Uro Pipeline: FDA accepts biologics license application for bladder Ca agentOther pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
Convective water vapor ablation successful at 2 yearsA treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.
Can BPH and prostate cancer be prevented?This review focuses on primary prevention of BPH and prostate cancer.
New Products: Neuromodulation system for OAB targets tibial nerveOther products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.
Basic Science Research: Trimodal therapy shows promise in oligometastatic PCaOther basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.
BPH: Current, forthcoming modalities show efficacyFour-year data on the prostatic urethral lift (UroLift) and data on a new water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting.
UroLift vs. TURP: New gold standard for BPH?In this video, Neil Baum, MD, compares UroLift with other BPH management strategies and also discusses his experience with the use of nitrous oxide as an effective sedative during in-office urologic procedures.